Denver PWM LLC Purchases 19,116 Shares of Immunome, Inc. (NASDAQ:IMNM)

Denver PWM LLC lifted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 95.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 39,116 shares of the company’s stock after acquiring an additional 19,116 shares during the quarter. Denver PWM LLC’s holdings in Immunome were worth $473,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Jump Financial LLC purchased a new position in shares of Immunome during the fourth quarter worth about $172,000. Mayo Clinic purchased a new stake in Immunome in the fourth quarter worth about $1,161,000. Avidity Partners Management LP purchased a new stake in Immunome in the fourth quarter worth $14,268,000. Clear Creek Financial Management LLC purchased a new stake in shares of Immunome in the 1st quarter worth about $547,000. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Immunome in the 1st quarter worth approximately $1,044,000. Institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

NASDAQ IMNM opened at $14.22 on Friday. The company has a market capitalization of $852.76 million, a price-to-earnings ratio of -1.88 and a beta of 1.77. Immunome, Inc. has a one year low of $6.13 and a one year high of $30.96. The company’s 50-day simple moving average is $13.95 and its two-hundred day simple moving average is $16.88.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IMNM. Piper Sandler lowered their price objective on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $29.00.

Insider Buying and Selling

In related news, insider Jack Higgins sold 3,524 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the transaction, the insider now directly owns 16,000 shares of the company’s stock, valued at approximately $222,880. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the sale, the insider now owns 16,000 shares in the company, valued at $222,880. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $13.94 per share, with a total value of $97,580.00. Following the completion of the purchase, the director now owns 16,615 shares in the company, valued at $231,613.10. The disclosure for this purchase can be found here. 8.60% of the stock is owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.